Venus Remedies Ltd, a leading player in India’s generic drug manufacturing sector, has recently been awarded a pivotal disbursement of Rs 7.5 crore under the Central Government’s Production Linked Incentive (PLI) scheme for the financial year 2022-23. This disbursement, which represents 75% of the total incentive due to the company for the year, marks a […]
Bajaj Healthcare Ltd., a prominent figure in the pharmaceutical industry specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), Intermediates, and Formulations, has announced a significant development. The company has entered into a definitive Contract Development and Manufacturing Organization (CDMO) agreement with esteemed customers based in the UK and EU for the supply of 15 […]
Global pharmaceutical major, Lupin Limited (Lupin), has announced receiving the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Mandideep Unit-2 manufacturing facility. This report, indicating a significant milestone, was issued following the facility’s recent inspection, held from August 7 to August 11, 2023. Remarkably, the inspection concluded […]
Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase 2 clinical trial. The trial aims to evaluate its ready-to-use, room temperature-stable glucagon in patients with Type 1 diabetes who suffer from exercise-induced hypoglycemia (EIH). This is a critical step for the company as it looks to […]
Global investment firm Blackstone has announced the acquisition of AYUMI Pharmaceutical, a leading Japanese specialty pharma company, marking its first controlling private equity investment in Japan. The deal was made through Blackstone-managed private equity funds, though the purchase price remains undisclosed. Blackstone’s Strategic Move into Japan’s Pharma Sector Blackstone’s acquisition of AYUMI Pharmaceutical represents a […]
Aurobindo Pharma, a prominent Indian pharmaceutical company, has agreed to a significant acquisition from Sandoz US, a division of the Swiss pharmaceutical giant Novartis. The deal, valued at approximately $1 billion, involves the purchase of Sandoz’s dermatology business and a diverse portfolio of oral solid products, along with commercial and manufacturing infrastructure. The transaction terms […]
Avara Pharmaceutical Services, a prominent US-based contract development and manufacturing organization (CDMO), has successfully completed the acquisition of a sterile manufacturing facility for injectable medicines located in Boucherville, Quebec. This strategic acquisition, initially announced in late May 2018, marks Avara’s first foray into the Canadian market and significantly enhances its capabilities in sterile processing. The […]
Olon, a prominent developer and manufacturer of active pharmaceutical ingredients (API) based in Italy, has strategically expanded its global operations with the acquisition of a generics chemical operations API manufacturing plant located in Mahad, Maharashtra, India. This move is part of Olon’s ambitious strategy to accelerate growth by incorporating new Contract Development and Manufacturing Organization […]
LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant deal valued at approximately KRW 450 billion ($402 million). This licensing agreement, however, excludes South Korea, where JWP will retain exclusive rights. Under the terms of the agreement, LEO Pharma […]
Dutch pharmaceutical giant Norgine has inaugurated new offices in Wettenberg, Germany, marking a significant step in its ongoing growth strategy. This move strengthens its commitment to its largest product sales market, where it has been a key player since 1928. The new facility is set to enhance the company’s operations and support services, ensuring the […]